MedPath

Extension Study of ABP-671 in Participants With Gout

Phase 2
Conditions
Gout
Interventions
Registration Number
NCT06276556
Lead Sponsor
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
Brief Summary

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
580
Inclusion Criteria
  • Must have completed the double-blind Treatment Period in Study ABP-671-301 (Part 1 or Part 2) and are actively receiving and tolerating the study drug up to the Week 28 visit in Study ABP-671-301
Exclusion Criteria
  • Has a new medical or psychological condition that, in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the participant, interfere with the participant's ability to comply with the protocol requirements to complete the Extension Study, or potentially compromise the results or interpretation of the Extension Study.
  • Is planning to become pregnant or breastfeed during the study or within โ‰ค30 days after the last dose of the study drug.
  • Is intolerant or unwilling to take colchicine or naproxen.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AllopurinolAllopurinol-
ABP-671ABP-671-
Primary Outcome Measures
NameTimeMethod
Incidence of treatment-emergent adverse events (Safety and Tolerability)Week 26

Incidence of treatment-emergent adverse events (TEAEs), including AEs of special interest (AESIs), serious AEs (SAEs), and AEs leading to study treatment discontinuation

Proportion of participants who achieve serum uric acid (sUA) levels <6.0 mg/dL (<0.360 mmol/L)Week 26
Secondary Outcome Measures
NameTimeMethod
Proportion of participants who achieve sUA levels <5.0 mg/dL (<0.300 mmol/L)Week 26

Trial Locations

Locations (54)

Tucson Neuroscience Research, LLC

๐Ÿ‡บ๐Ÿ‡ธ

Tucson, Arizona, United States

New Horizons Research

๐Ÿ‡บ๐Ÿ‡ธ

Palmetto Bay, Florida, United States

DelRicht Research of Gulfport

๐Ÿ‡บ๐Ÿ‡ธ

Gulfport, Mississippi, United States

Annapolis Internal Medicine/CCT Research

๐Ÿ‡บ๐Ÿ‡ธ

Annapolis, Maryland, United States

Emeritus Research Sydney

๐Ÿ‡ฆ๐Ÿ‡บ

Botany, New South Wales, Australia

Paratus Clinical Research Western Sydney

๐Ÿ‡ฆ๐Ÿ‡บ

Blacktown, New South Wales, Australia

Austin Health - Repatriation Hospital

๐Ÿ‡ฆ๐Ÿ‡บ

Heidelberg, Victoria, Australia

A R Houston Medical Pty Ltd

๐Ÿ‡ฆ๐Ÿ‡บ

Kippa-Ring, Queensland, Australia

Cheng-Shin General Hospital

๐Ÿ‡จ๐Ÿ‡ณ

Taipei City, Taiwan

Chang Gung Memorial Hospital CGMH

๐Ÿ‡จ๐Ÿ‡ณ

Kaohsiung City, Taiwan

Nature Coast Clinical Reasearch

๐Ÿ‡บ๐Ÿ‡ธ

Crystal River, Florida, United States

Bioclinical Research Alliance

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

A & D Doctor Center

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Cordova Research Institute

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Century Research LLC

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

ITB Research

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Alliance for Multispecialty Research, LLC.

๐Ÿ‡บ๐Ÿ‡ธ

Newton, Kansas, United States

Santa Rosa Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Las Vegas, Nevada, United States

Quality Research Inc.

๐Ÿ‡บ๐Ÿ‡ธ

San Antonio, Texas, United States

Worldwide Clinical Trials

๐Ÿ‡บ๐Ÿ‡ธ

San Antonio, Texas, United States

AMR

๐Ÿ‡บ๐Ÿ‡ธ

New Orleans, Louisiana, United States

Alliance for Multispecialty Research

๐Ÿ‡บ๐Ÿ‡ธ

Tempe, Arizona, United States

ClinSearch

๐Ÿ‡บ๐Ÿ‡ธ

Chattanooga, Tennessee, United States

Medical Care/CCT

๐Ÿ‡บ๐Ÿ‡ธ

Elizabethton, Tennessee, United States

Academician Vakhtang Bochorishvili Clinic

๐Ÿ‡ฌ๐Ÿ‡ช

Tbilisi, Georgia

Clรญnica Mรฉdica Especializada en Medicina Interna

๐Ÿ‡ฌ๐Ÿ‡น

Guatemala city, Guatemala

Buddhist Dalin Tzu Chi General Hospital

๐Ÿ‡จ๐Ÿ‡ณ

Chiayi City, Taiwan

Emeritus Research Melbourne

๐Ÿ‡ฆ๐Ÿ‡บ

Camberwell, Victoria, Australia

Aversi Clini

๐Ÿ‡ฌ๐Ÿ‡ช

Tbilisi, Georgia

Innova

๐Ÿ‡ฌ๐Ÿ‡ช

Tbilisi, Georgia

New Hospitals

๐Ÿ‡ฌ๐Ÿ‡ช

Tbilisi, Georgia

The First Medical Center

๐Ÿ‡ฌ๐Ÿ‡ช

Tbilisi, Georgia

Clinical Research Center (CRC)

๐Ÿ‡ฌ๐Ÿ‡น

Guatemala city, Guatemala

Evex Hospitals Caraps Medline

๐Ÿ‡ฌ๐Ÿ‡ช

Tbilisi, Georgia

Chung Shan Medical Univ. Hospital

๐Ÿ‡จ๐Ÿ‡ณ

Taichung, Taiwan

Chang Gung Memorial Hospital LinKou

๐Ÿ‡จ๐Ÿ‡ณ

Taoyuan, Taiwan

Clรญnica Mรฉdica Especializada en Medicina Interna y Reumatologรญa

๐Ÿ‡ฌ๐Ÿ‡น

Guatemala city, Guatemala

Quality Clinical Research, Inc

๐Ÿ‡บ๐Ÿ‡ธ

Omaha, Nebraska, United States

Paratus Clinical Research Central Coast

๐Ÿ‡ฆ๐Ÿ‡บ

Kanwal, New South Wales, Australia

Anaheim Clinical Trials (Cenexel ACT)

๐Ÿ‡บ๐Ÿ‡ธ

Anaheim, California, United States

Accel Clinical Research Site

๐Ÿ‡บ๐Ÿ‡ธ

DeLand, Florida, United States

Access Research Institute

๐Ÿ‡บ๐Ÿ‡ธ

Brooksville, Florida, United States

Jacksonville Center for Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Jacksonville, Florida, United States

JY Research Institute Inc.

๐Ÿ‡บ๐Ÿ‡ธ

Cutler Bay, Florida, United States

Advanced Clinical Research of Atlanta

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

Centricity Research

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Georgia, United States

Inspire Santa Fe Medical Group

๐Ÿ‡บ๐Ÿ‡ธ

Santa Fe, New Mexico, United States

OnSite Clinical Solutions

๐Ÿ‡บ๐Ÿ‡ธ

Salisbury, North Carolina, United States

Altoona Center for Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Duncansville, Pennsylvania, United States

PanAmerican Clinical Research, LLC

๐Ÿ‡บ๐Ÿ‡ธ

Brownsville, Texas, United States

Clรญnica Mรฉdica Especializada en Medicina Interna y Reumatologรญa (CREER)

๐Ÿ‡ฌ๐Ÿ‡น

Guatemala city, Guatemala

Center for Clinical Trials of Sacramento

๐Ÿ‡บ๐Ÿ‡ธ

Sacramento, California, United States

Combined Research Orlando Phase I-IV

๐Ÿ‡บ๐Ÿ‡ธ

Orlando, Florida, United States

DelRicht Research

๐Ÿ‡บ๐Ÿ‡ธ

New Orleans, Louisiana, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath